Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. [electronic resource]
Producer: 20170807Description: 228-238 p. digitalISSN:- 1941-837X
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.